| Catalog No. | AF687014 |
|---|
| Applications | ELISA |
|---|
| Host species | Rabbit |
|---|
| Isotype | IgG |
|---|
| Clonality |
Polyclonal |
| Immunogen |
Eculizumab |
| Target |
Rabbit polyclonal to Soliris. |
| Specificity |
The product is specific for Eculizumab. This antibody serves as an excellent positive control for Eculizumab immunogenicity (ADA) assays. |
| Endotoxin level |
Please contact with the lab for this information. |
| Purification |
Purified by antigen affinity column. |
| Accession |
CAS: 219685-50-4 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Product Usage Information |
| Application |
Dilution |
| ELISA |
1:5000-1:20000 |
| IHC |
1:50-1:500 |
| WB |
1:500-1:2000 |
|
|---|
| Stability and Storage |
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles. |
| Background | Eculizumab with trade name Soliris, is an FDA-approved drug to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica. Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5. Eculizumab specifically binds to the terminal complement component 5, or C5. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.
• Induction Immunosuppression in High-risk Kidney Transplant Recipients., PMID:27041548
• Acute Rejection Following Kidney Transplantation: State-of-the-Art and Future Perspectives., PMID:32520680
• The impact of terminal complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globulin in living donor renal allografts., PMID:22813834
|
|---|
| Note |
For research use only. |
中文
English
